Klin Farmakol Farm. 2022;36(4):136-139 | DOI: 10.36290/far.2022.022

Drug-induced tremors

Pavel Filip1, 2, Marek Baláž3
1 Neurologická klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecné fakultní nemocnice v Praze
2 Center for Magnetic Resonance Research (CMRR), University of Minnesota, Minneapolis, MN, USA
3 1. neurologická klinika, Fakultní nemocnice u sv. Anny, Brno

Tremor is the most common movement disorder with several potential causes. There is a multitude of drugs utilised in the clinical practice, which may exacerbate or even cause tremor, the most common ones being amiodarone, valproate, dopamine receptor antagonists, lithium, selective serotonin (and norepinephrine) reuptake inhibitors (SSRI/SNRI) and amitriptyline. Drug-induced tremors usually correspond to enhanced physiological tremor, but, depending on the causal drug, the tremor may be a part of drug-induced parkinsonism. The recognition of tremorgenic drugs may help quick diagnosis, avoid unnecessary tests and lead to adequate actions - usually dose decrease or discontinuation of relevant drug, or its substitution. The aim of this review is to provide physicians and pharmacists with current information on the groups of drugs where a potential association with tremor is to be considered, including the information on possible management of this complication.

Keywords: drug-induced tremor, pathophysiology, drug-induced movement disorders.

Accepted: February 8, 2023; Published: February 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Filip P, Baláž M. Drug-induced tremors. Klin Farmakol Farm. 2022;36(4):136-139. doi: 10.36290/far.2022.022.
Download citation

References

  1. Morgan JC, Sethi KD. Drug-induced tremors. Lancet Neurol. 2005;4(12):866-876. Go to original source... Go to PubMed...
  2. Factor SA. Lithium-induced movement disorders. In: Drug-induced movement disorders. CRC Press; 2004. s. 226-249. Go to original source...
  3. Sethi KD, Patel B, Meador KJ. Metoclopramide-induced parkinsonism. South Med J. 1989;82(12):1581-1582. Go to original source... Go to PubMed...
  4. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci. 1990;2(1):64-66. Go to original source... Go to PubMed...
  5. Baizabal-Carvallo JF, Morgan JC. Drug-induced tremor, clinical features, diagnostic approach and management. J Neurol Sci. 2022;435:120192. Go to original source... Go to PubMed...
  6. Langone A, Steinberg SM, Gedaly R, Chan LK, Shah T, Sethi KD, et al. Switching ST udy of Kidney TRansplant PA tients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015;29(9):796-805. Go to original source... Go to PubMed...
  7. Morgan JC, Kurek JA, Davis JL, Sethi KD. Insights into pathophysiology from medication-induced tremor. Tremor Hyperkinetic Mov. 2017;7. Go to original source...
  8. Bongard V, Marc D, Philippe V, Jean-Louis M, Maryse LM. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther. 2006;13(4):315-319. Go to original source... Go to PubMed...
  9. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacother J Hum Pharmacol Drug Ther. 1998;18(6P2):138S-145S. Go to original source...
  10. Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. Am Heart J. 1983;106(4):916-923. Go to original source... Go to PubMed...
  11. Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol. 1987;65(3):360-364. Go to original source... Go to PubMed...
  12. Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1989;25(6):630-632. Go to original source... Go to PubMed...
  13. Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, Basquedano G, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther. 1998;20(3):467-476. Go to original source... Go to PubMed...
  14. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-546. Go to original source... Go to PubMed...
  15. Garel N, Greenway KT, Tabbane K, Joober R. Serotonin syndrome: SSRIs are not the only culprit. J Psychiatry Neurosci. 2021;46(3):E369-70. Go to original source... Go to PubMed...
  16. Watanabe S, Yokoyama S, Kubo S, Iwai H, Kuyama C. A double-blind controlled study of clinical efficacy of maprotiline and amitriptyline in depression. Psychiatry Clin Neurosci. 1978;32(1):1-31. Go to original source... Go to PubMed...
  17. Baek JH, Kinrys G, Nierenberg AA. Lithium tremor revisited: pathophysiology and treatment. Acta Psychiatr Scand. 2014;129(1):17-23. Go to original source... Go to PubMed...
  18. Zadikoff C, Munhoz RP, Asante AN, Politzer N, Wennberg R, Carlen P, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry. 2007;78(2):147-151. Go to original source... Go to PubMed...
  19. Zhang CQ, He BM, Hu ML, Sun HB. Risk of valproic acid-related tremor: a systematic review and meta-analysis. Front Neurol. 2020;11:576579. Go to original source... Go to PubMed...
  20. Paparella G, Angelini L, De Biase A, Cannavacciuolo A, Colella D, Di Bonaventura C, et al. Clinical and kinematic features of valproate-induced tremor and differences with essential tremor. The Cerebellum. 2021;20(3):374-383. Go to original source... Go to PubMed...
  21. Kovács A, Farkas Z, Kelemen A, Juhos V, Sz\\Hucs A, Kamondi A. Lamotrigine induces tremor among epilepsy patients probably via cerebellar pathways. Tohoku J Exp Med. 2019;248(4):273-284. Go to original source... Go to PubMed...
  22. Alonso-Navarro H, Jiménez-Jiménez FJ. Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine. Clin Neuropharmacol. 2006;29(3):157-159. Go to original source... Go to PubMed...
  23. Rissardo JP, Caprara ALF. Pregabalin-associated movement disorders: A literature review. Brain Circ. 2020;6(2):96. Go to original source... Go to PubMed...
  24. Shanker V. Essential tremor: diagnosis and management. bmj. 2019;366.
  25. Mazer B, Figueroa-Rosario W, Bender B. The effect of albuterol aerosol on fine-motor performance in children with chronic asthma. J Allergy Clin Immunol. 1990;86(2):243-248. Go to original source... Go to PubMed...
  26. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol. 1996;49(2):247-250. Go to original source... Go to PubMed...
  27. Baker MR, Baker SN. Beta-adrenergic modulation of tremor and corticomuscular coherence in humans. PLoS One. 2012;7(11):e49088. Go to original source... Go to PubMed...
  28. Sethi KD. Movement disorders induced by dopamine blocking agents. In: Seminars in neurology. Copyright\\copyright 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New …; 2001. s. 059-68. Go to original source...
  29. Stacy M, Jankovic J. Tardive tremor. Mov Disord Off J Mov Disord Soc. 1992;7(1):53-57. Go to original source... Go to PubMed...
  30. Kertesz DP, Swartz MV, Tadger S, Plopski I, Barak Y. Tetrabenazine for tardive tremor in elderly adults: a prospective follow-up study. Clin Neuropharmacol. 2015;38(1):23-25. Go to original source... Go to PubMed...
  31. Calne DB, Webster RA. Tremor induced by tetrabenazine. Br J Pharmacol. 1969;37(2):468. Go to original source... Go to PubMed...
  32. Acharya SR, Kumar TN, Vasshadhara C. Metoclopramide-a cholinomimetic tremorogen? In: Metoclopramide-a cholinomimetic tremorogen? 1982.
  33. Graber DJ, Meier KH. Acute misoprostol toxicity. Ann Emerg Med. 1991;20(5):549-551. Go to original source... Go to PubMed...
  34. Bateman DN, Bevan P, Longley BP, Mastaglia F, Wandless I. Cimetidine induced postural and action tremor. J Neurol Neurosurg Psychiatry. 1981;44(1):94. Go to original source... Go to PubMed...
  35. Mandel SH, Magnusson AR, Burton BT, Swanson JR, LaFranchi SH. Massive levothyroxine ingestion: conservative management. Clin Pediatr (Phila). 1989;28(8):374-376. Go to original source... Go to PubMed...
  36. Abila B, Lazarus JH, Kingswood JC, Marshall RW, Wilson JF, Richens A. Tremor: an alternative approach for investigating adrenergic mechanisms in thyrotoxicosis? Clin Sci Lond Engl 1979. 1985;69(4):459-463. Go to original source... Go to PubMed...
  37. Falkson G, Falkson HC. A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer. Cancer Chemother Pharmacol. 1983;11(1):16-18. Go to original source... Go to PubMed...
  38. Simons FER, Gu X, Silver NA, Simons KJ. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol. 2002;109(1):171-175. Go to original source... Go to PubMed...
  39. Gijtenbeek JM, Van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246(5):339-346. Go to original source... Go to PubMed...
  40. Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA. FK506-induced neurotoxicity in liver transplantation. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1994;35(4):498-501. Go to original source... Go to PubMed...
  41. Sarasombath P, Sumida KN, Kaku DA. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. Hawaii Med J. 2002;61(3).
  42. Vogrig A, Muñiz-Castrillo S, Joubert B, Picard G, Rogemond V, Marchal C, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020;91(7):772-778. Go to original source... Go to PubMed...
  43. Xing F, Marsili L, Truong DD. Parkinsonism in viral, paraneoplastic, and autoimmune diseases. J Neurol Sci. 2022;433:120014. Go to original source... Go to PubMed...
  44. Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol-Neuroimmunol Neuroinflammation. 2019;6(6).
  45. Borucki MJ, Matzke DS, Pollard RB. Tremor induced by trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;109(1):77-78. Go to original source... Go to PubMed...
  46. Burdge DR, Chow AW, Sacks SL. Neurotoxic effects during vidarabine therapy for herpes zoster. Can Med Assoc J. 1985;132(4):392. Go to PubMed...
  47. Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM. Distinguishing acyclovir neurotoxicity from encephalomyelitis. J Intern Med. 1993;234(5):507-511. Go to original source... Go to PubMed...
  48. Ellis WG, Sobel RA, Nielsen SL. Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis. 1982;146(2):125-137. Go to original source... Go to PubMed...
  49. Quabeck K, Müller KD, Beelen DW, Dermoumi H, Kölbel M, Kraft J, et al. Prophylaxis and treatment of fungal infections with fluconazole in bone marrow transplant patients. Mycoses. 1990;33(1S):19-26. Go to original source...
  50. Chiruka S, Chapman CS. Severe tremors associated with use of thalidomide. Am J Hematol. 2005;78(1):81-82. Go to original source... Go to PubMed...
  51. Dworkin LA, Goldman RD, Zivin LS, Fuchs PC. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol. 1985;3(5):613-616. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.